Healthcare giant Johnson & Johnson (JNJ) reported a beat on both the top and bottom line expectations as it posted its Q2 2018 earnings. This was aided by a double-digit growth in Pharmaceutical business and the accelerating sales momentum in the Medical Devices business.
During the quarter, the company posted EPS of $1.45. Excluding items, EPS grew 14% to $2.10, topping analysts’ expectation of $2.06 per share. Revenue came in at $20.8 billion, beating the consensus of $20.37 billion.
For the past four quarters, the company has put together impressive earnings results topping analysts estimates, thanks to a booming pharmaceutical segment. Cancer drugs Imbruvica and Darzalex aided most of this growth. Despite stiff competition from biosimilars, the company managed to post a double-digit sales growth during the quarter. The pharma segment posted sales of $10.4 billion, an increase of 19.9% versus the prior year.
The firm updated its sales guidance for full-year 2018 to a range of $80.5 billion – $81.3 billion. Johnson’s also updated its adjusted earnings guidance for full-year 2018 to a range of $8.07 – $8.17 per share.
Separately, the company’s board declared a cash dividend of $0.90 per share for the Q3 2018 on the company’s common stock. The dividend is payable on September 11, 2018 to shareholders of record on August 28, 2018.
The company has a strong financial position and should not have much trouble paying $4.7 billion in damages for a lawsuit it lost recently over its talc products. However, there are about 9,000 more similar cases pending against the company.
During pre-market trading, JNJ shares rose 0.49% to $125.30.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,